Is a leading global industrial gases and engineering company with 2019 sales of We are inspired by a vision to enable patients withĬhronic conditions to remain engaged in life, with the peace of mind that we Is to set the standard for excellence, transforming the way respiratory care isĭelivered in the home. Medications, Enteral Therapy, and Durable Medical Equipment. Respiratory Therapy, Sleep Therapy, INR Testing, Nebulizer and Respiratory Geographic reach, offering an extensive portfolio of quality products and services: provider of respiratory care in the home with a broad Nurses, caregivers, and clinical staff who are dedicated to providing anĮxcellent standard of care to patients nationwide.” We stand with our fellow healthcare providers - doctors, This includesĪdhering to industry standards and protocols to help ensure the safety of our Industry, Lincare is taking all necessary steps to play an active role inįighting this pandemic as a trusted provider for our patients. Pandemic,” said Lincare CEO Crispin Teufel. Respiratory medications, as well as ventilation services.Īnd reliably provide critical in-home services throughout the COVID-19 Lincare patients who have tested positive forĬOVID-19 have received respiratory services including oxygen and nebulized Hospital capacity for patients requiring critical care. Patients who are eligible for in-home care, which results in additional The burden on hospitals across the country by partnering with them to transition In caring for patients at home, including some who have tested positive for – Lincare, a subsidiary of Linde (NYSE:LIN FWB:LIN) is playing a critical role Helping to increase critical hospital capacity by transitioning respiratory patients and others from in-patient to in-home care.Providing in-home services to patients with underlying chronic medical conditions who may be more vulnerable when contracting COVID-19.supported by more than 2,000 Lincare clinicians. Ensuring continued care to 1.6 million patients across the U.S.Throughout this pandemic, Lincare remains committed to: The transaction marks KabaFusion’s first acquisition since partnering with Pritzker Private Capital in January 2019.Lincare, a subsidiary of Linde (NYSE:LIN FWB:LIN), the leading provider of home respiratory care in the U.S., stands as a second line of defense in support of efforts to address the COVID-19 (coronavirus) public healthcare crisis. Terms of the transaction were not disclosed. KabaFusion’s clinician-led management team will continue to lead the combined company in working with patients, healthcare providers, hospitals and payors across the United States to deliver the highest quality home infusion services with unmatched clinical excellence. Sohail Masood, Pharm D., in 2010, Chief Executive Officer, KabaFusion has been a pioneering leader in patient-focused home infusion services with deep clinical expertise in intravenous immunoglobulin (IVIG) therapies. Together with KabaFusion’s existing pharmacies in California, Florida, Illinois, Massachusetts, New Jersey, Pennsylvania and Texas, the company is licensed to serve patients in 44 states with a comprehensive offering of acute, chronic and enteral therapies.įounded by Dr. The addition of Lincare’s infusion operations expands KabaFusion’s footprint to 28 home infusion specialty pharmacies, adding key strategic markets in Alabama, Arkansas, Florida, Indiana, Kentucky, Michigan, New Jersey, New York, North Carolina, Virginia and Wyoming. The amount of the deal was not disclosed. KabaFusion, a Cerritos, Calif.-based provider of specialty acute and chronic home infusion therapies, acquired the home infusion assets of Lincare, a subsidiary of Linde plc.
0 kommentar(er)
